EU Rare Diseases Action Plan 2026: 5 Policy Shifts to Address Unmet Needs

The EU rare diseases action plan is moving from aspiration to concrete policy, and the decisive step came at the 13th European Conference on Rare Diseases & Orphan Products (ECRD 2026). Held in Prague on 3 and 4 June 2026, the conference launched a multi-stakeholder process to build a European Action Plan for Rare Diseases and to refine the European Blueprint for Rare Diseases, a roadmap whose full publication is planned for September 2026. For the estimated 30 million Europeans living with a rare condition, this is the clearest signal yet that fragmented national efforts are being consolidated into a single, coordinated European strategy.

EU Rare Diseases Action Plan: Shaping policy to address unmet needs in Europe

According to EURORDIS-Rare Diseases Europe, ECRD 2026 united over 500 participants in Prague and more than 200 online, alongside a closed high-level meeting attended by ministers and senior officials from 14 EU Member States. The message was unambiguous: rare diseases are a test case for EU added value, because no single country can dismantle the fragmentation alone.

The European Conference on Rare Diseases: A Catalyst for Change

ECRD 2026 functioned as the engine room for the emerging rare disease policy in Europe. Convened by EURORDIS under the theme "Rare Diseases in a Changing & Competitive Europe", the conference did not merely review progress; it launched a community-led effort to co-develop an EU Action Plan and feed directly into the European Blueprint.

The timing was deliberate. The conference took place five years after the Rare2030 foresight study and midway to the WHO Global Action Plan horizon, at a point where the European Commission had not yet committed to a formal action plan. That gap is precisely what stakeholders in Prague set out to close.

Avril Daly, President of EURORDIS, captured the mood: "Every day counts for the 30 million Europeans living with rare diseases. A unified EU Action Plan will transform scattered initiatives into coordinated impact." She added that "securing adequate funding is now the central test of political seriousness", pointing to the EU's Multiannual Financial Framework as the true measure of intent.

The European Blueprint: A Roadmap for Action

The European Blueprint for Rare Diseases is the practical foundation for the future action plan. It is designed to consolidate existing initiatives, identify the gaps between them, and translate shared political intent into implementable recommendations, with publication scheduled for September 2026.

According to EURORDIS, the Blueprint is structured around two integrated pillars. The first sets out the foundations for a future EU Action Plan on Rare Diseases. The second defines the WHO European Region's contribution to a Global Action Plan on Rare Diseases. This dual design means European reforms are aligned with global commitments rather than duplicating them.

Therapy development and equitable access to treatments across Member States.
Timely and accurate diagnosis, ending the long diagnostic journeys patients endure.
Research, prevention and evidence-based holistic care, including specialised healthcare access.
Health technology assessment and reimbursement, so approved therapies actually reach patients.
The mental health dimension of living with a rare condition, an area long overlooked.

Addressing Unmet Needs: Diagnosis, Care, and Innovation

The scale of unmet need is stark. In its draft report of 5 March 2026, the European Parliament's Committee on Public Health (SANT) estimated that between 27 and 36 million people across the EU live with a rare disease, and that roughly 95% of rare conditions still lack an authorised treatment. The report, led by MEP rapporteur Nicolás González Casares, drew on a 2025 consultation with over 4,000 participants and called on the European Commission to propose legislation for a comprehensive European rare disease framework.

Innovation access is the sharpest pressure point. The EU Health Technology Assessment Regulation has applied to oncology medicines and advanced therapy medicinal products since January 2025 and will extend to orphan products in January 2028. The processes being built now will determine whether patients with rare diseases genuinely benefit. As Daria Julkowska, ERDERA Scientific Coordinator, warned in June 2026: "Regulators are increasingly open to dialogue and innovation, but we are not yet there on health technology assessment."

The Social Impact: What Fragmentation Means for Ordinary Families

Behind the policy language are households under sustained strain. When 95% of rare conditions have no authorised treatment, families in Spain, Poland or Belgium may travel to Germany, France or the Netherlands for expertise that does not exist at home, absorbing travel, accommodation and lost-income costs that low-income households cannot easily bear. A diagnosis that arrives late can mean years of unnecessary tests, misdirected treatment and children falling behind at school.

The consequences fall hardest on vulnerable groups: children, patients in smaller Member States with fewer specialist centres, and families without the resources to navigate cross-border care. This is why patient representatives insist the action plan must include social support, not only clinical measures. Valentina Bottarelli, Head of Policy and Public Affairs at EURORDIS, argued that "rare diseases cannot be addressed through fragmented national policies alone" and that policies "must be developed with patients, not only for them". Readers can follow this evolving story through our ongoing health articles.

The Power of Collaboration: Why Europe Needs a Unified Approach

Rare diseases are, by definition, thinly spread across borders, which makes them the strongest possible argument for pooling expertise. European Reference Networks (ERNs) were highlighted at ECRD 2026 as core EU added value requiring stable, ringfenced funding. Virginie Hivert, Acting Chief Executive Officer of EURORDIS, described ERNs as "the central space where patients, clinicians, researchers, regulators and innovators genuinely work together", and said patient input should be treated as "a genuine competitive advantage for Europe".

The political framing matters too. At the December 2025 High-Level Meeting in Brussels, MEP Vytenis Andriukaitis called rare diseases "a test of Europe's capacity to act with courage and conviction", while meeting host Professor Maurizio Scarpa noted they "reveal both Europe's strengths and its vulnerabilities". Infrastructure such as the European Health Data Space and the EU Biotech Act are viewed as levers to connect research and speed up clinical trials.

Looking Ahead: Implementation and Impact of the Action Plan

The immediate milestone is the Blueprint's publication in September 2026, which will hand policymakers a ready-made template. The harder task is turning recommendations into binding commitments backed by money. Jean Saslawsky, EURORDIS Chief Executive Officer, opened his mandate at ECRD 2026 with what he described as "a listening posture over the two days", signalling a phase of consolidation before advocacy intensifies. The real measure of success will be whether the next Multiannual Financial Framework earmarks dedicated resources for programmes such as ERDERA and JARDIN, and whether the Commission ultimately proposes legislation.

What EU Patients and Advocates Can Do Now

Engage with EURORDIS and national alliances: join consultations feeding into the Blueprint before its September 2026 publication.
Ask about European Reference Networks: request that your specialist confirms whether an ERN covers your condition, to access cross-border expertise.
Contact your MEP: support the European Parliament's SANT report and press for a funded EU Action Plan.
Document your care journey: patient-reported evidence strengthens the case for shorter diagnosis and reimbursement reform.
Check official sources: follow the European Commission for legislative announcements, and our Baba International coverage for analysis.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

What is the EU rare diseases action plan?

It is a proposed EU-wide framework to align policies on diagnosis, care, research and access to treatment for rare diseases. Its foundation is the European Blueprint for Rare Diseases, advanced at ECRD 2026 in Prague and due for publication in September 2026.

How many people in the EU have a rare disease?

EURORDIS estimates around 30 million Europeans, while the European Parliament's SANT committee draft report of 5 March 2026 cites a range of 27 to 36 million people across the EU.

When will the European Blueprint for Rare Diseases be published?

EURORDIS has stated the Blueprint's publication is planned for September 2026, following the multi-stakeholder process launched at ECRD 2026 on 3 and 4 June 2026.

Why can a single Member State not solve rare diseases alone?

Because each condition affects very few people and expertise is scattered across borders. Roughly 95% of rare conditions still lack an authorised treatment, so pooling data, research and specialist care through EU structures like European Reference Networks is essential for equitable access.